{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Ftyk2-2PbOnGcJ","width":444,"version":"1.0","type":"rich","title":"It Takes Two to TYK-2 PART 1: Zooming in on Deucravacitinib and What It Means for Your Patients with PsO","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/a4232b1c-e96b-4eac-afd3-0f53026a17b9/tyk2-part-1.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"🎧 TYK-TOK we’re ready to rock.\n\n🎙️🎙️ The Skin and Joints Podcast Team is starting 2023 off strong with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.\n\n🛎️ Deucravacitinib is finally here!\n\n🧵How does it compare with other biologics and non-biologic treatments?\n\n🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? \n\n\n\nEpisode Learning Objectives\n\nApply current evidence as well as shared decision-making to individualize therapy decisions for patients with moderate to severe plaque psoriasis; specifically deucravacitinib, a novel oral TYK2 inhibitor (PART 1)\n\nExamine key real world considerations between TYK2 inhibitors with JAK inhibitors in terms of safety and tolerability (PART 1)\n\nExplore the correlations between responses on clinical and PRO measures in pooled data from POETYK PSO-1 and PSO-2 (PART 2)\n\nEvaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis subgroup analyses pooled PSO-1 and PSO-2 data (PART 2)\n\n\n\nEpisode supported by an IME Grant from BMS. \n"}